# Innate Pharma SA (IPHA)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001598599 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001598599))
- Full page: https://inspectstocks.com/stocks/ipha
- Data as of: price 2026-09-25; newest filing used 2026-09-17; latest fiscal period ended 2026-06-30

## Grade

**F-** on the growth-and-cash rubric, 0 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Revenue growing overall | failed |  |  |
| Revenue growing recently | failed |  |  |
| Free cash flow positive | failed |  |  |
| Free cash flow growing overall | failed |  |  |
| Free cash flow growing recently | failed |  |  |

Business quality (the + / − mark): 1 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed |  |  |
| Healthy profit margin | failed |  |  |
| Strong operating margin | failed |  |  |
| Good return on equity | passed |  |  |
| Turns sales into cash | failed |  |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, converted from EUR at today's spot rate (every period alike).

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $10.2M |
| Net income, trailing twelve months | -$56M |
| Free cash flow, trailing twelve months | -$60.2M |
| Net margin | -546.1% |
| Operating margin | -599.8% |
| Return on equity | 226.6% |
| Diluted EPS, trailing twelve months | -$0.63 |
| Share price | $1.70 |
| Market value | $159.3M |
| Price / sales | 15.5x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/ipha)
- [Financial statements](https://inspectstocks.com/stocks/ipha/financials)
- [Competitors](https://inspectstocks.com/stocks/ipha/peers)
- [Earnings](https://inspectstocks.com/stocks/ipha/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.